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Summary
 
Interleukin (IL)-4 is an immunoregulatory cytokine that exerts distinct biological activities on dif-
ferent cell types. Our studies indicate that interferon regulatory factor (IRF)-4 is both a target and
a modulator of the IL-4 signaling cascade. IRF-4 expression is strongly upregulated upon costim-
ulation of B cells with CD40 and IL-4. Furthermore, we find that IRF-4 can interact with signal
transducer and activator of transcription (Stat)6 and drive the expression of IL-4–inducible genes.
The transactivating ability of IRF-4 is blocked by the repressor factor BCL-6. Since expression of
IRF-4 is mostly confined to lymphoid cells, these data provide a potential mechanism by which
IL-4–inducible genes can be regulated in a lineage-specific manner.
Key words: CD40 • interleukin 4 • signal transducer and activator of transcription 6 • BCL-6 • 
interferon regulatory factor 4
 
I
 
nterleukin (IL)-4 is an immunoregulatory cytokine that
exerts a wide variety of effects on many different cell types
(1–3). IL-4 plays a central role in the regulation of immune
responses by promoting the differentiation of T helper cells
toward the Th2 subset. Furthermore, IL-4 synergizes with
stimuli provided by CD40 to drive B cell activation, prolif-
eration, and differentiation, thus strongly enhancing humoral
immunity (4).
IL-4 mediates its biological actions by activating a signal-
ing cascade, which follows the paradigm originally described
for the IFN signaling pathway (5–7). Binding of IL-4 to
its receptor leads to the activation, via Janus kinases (JAKs),
of a latent cytoplasmic protein, signal transducer and activa-
tor of transcription (STAT)
 
1
 
 6 (Stat6) (8). Tyrosine phosphor-
ylation of Stat6 allows it to homodimerize and rapidly
translocate into the nucleus where it modulates gene tran-
scription by binding to distinct cis-elements termed gamma-
activated sites (GAS). Although studies in Stat6-deficient
mice have demonstrated that Stat6 plays a key role in IL-4
signaling (9–11), additional factors are likely to participate
in this cascade. Indeed, the rapidity of Stat6 activation in
response to IL-4 cannot solely explain the inducibility of
IL-4 target genes like CD23, whose activation displays a
delayed kinetics (12). Moreover, tyrosine phosphorylation
of Stat6 in response to IL-4 has been detected in a wide va-
riety of cells (13–17). Thus, the differential gene expression
triggered by IL-4 in diverse cell types must involve the pres-
ence and/or recruitment of additional, possibly cell type–
specific, cofactors.
Consistent with the requirements for additional protein–
protein interactions in the regulation of IL-4–responsive
genes, the activity of Stat6 can be downregulated by B cell
lymphomas 6 (BCL-6). BCL-6 is a Krüppel zinc finger
transcriptional repressor that is highly expressed in germinal
center B cells and is frequently altered in non-Hodgkin lym-
phoma (18–21). BCL-6 has been shown to bind to the GAS
element in the CD23b promoter and repress Stat6-mediated
promoter function (22). Mice deficient in BCL-6 display lack
of germinal centers as well as an inflammatory disease charac-
terized by exaggerated Th2 responses including elevated levels
of serum IgG1 and IgE, supporting a role for BCL-6 as a re-
pressor of the IL-4 signaling pathway in vivo (22, 23). How-
ever, generation of mice deficient in both BCL-6 and Stat6
failed to abrogate the Th2 inflammatory disease, suggesting
that not all of the defects present in the BCL-6–deficient mice
can be simply ascribed to its repression of Stat6 function (24).
Studies of the IFN signaling pathway have demonstrated
that another family of transcription factors, the IFN regula-
tory factor (IRF) family, is both a target and a modulator of
this cytokine signaling cascade (25, 26). Genetic studies
have demonstrated a role for IRF proteins in the prolifera-
tion, differentiation, and apoptosis of a variety of immune
effector cells, suggesting the involvement of IRFs in path-
ways in addition to those triggered by the IFNs (27, 28). In
particular, lack of one of these newly cloned IRF proteins,
 
1
 
Abbreviations used in this paper:
 
 BCL-6, B cell lymphomas 6; EMSA, elec-
trophoretic mobility shift assay; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; GAS, IFN-
 
g
 
–activated site(s); GBP, guanylate binding
protein; GSH, glutathione; GST, GSH 
 
S
 
-transferase; ICSBP, IFN con-
sensus sequence binding protein; IRF, IFN regulatory factor; ISGF, IFN-
stimulated gene factor; ISRE, IFN-stimulated regulatory element; NF-
 
k
 
B,
nuclear factor 
 
k
 
B; STAT, signal transducer and activator of transcription;
WCE, whole cell extract; wt, wild-type. 
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IRF-4 (also termed Pip, LSIRF, ICSAT, or MUM1 [29–
32]), results in striking defects in the function of mature B
and T cells (33). Consistent with these results, expression of
both murine and human IRF-4 is mostly confined to the
lymphoid compartment and is induced in response to mi-
togenic stimuli (31, 32, 34). Functional studies have shown
that IRF-4 is involved in the transactivation of both the 
 
k
 
and 
 
l
 
 Ig light chain enhancers as well as the CD20 pro-
moter (29, 35–37). However, the effect of IRF-4 on these
enhancers is unlikely to explain the profound immunologi-
cal impairments demonstrated by the gene targeting stud-
ies. Additional IRF-4 targets and the physiological stimuli
that activate IRF-4 are unknown.
We are interested in understanding the downstream ef-
fectors of the IL-4 signaling pathways in B cells as well as
the mechanisms underlying the cross-talk between the CD40
and IL-4 signaling pathways. We focused our attention on
the regulation of the CD23 gene (38–41). CD23 induction
in response to IL-4 and CD40 occurs with delayed kinetics,
and displays a synergistic response when the two stimuli are
combined (12, 42, 43). In humans, CD23 exists as two al-
ternatively spliced isoforms, termed CD23a and CD23b,
which differ only in the intracytoplasmic domain. Expres-
sion of CD23a and CD23b is controlled by two separate
promoters (44). IL-4 inducibility of the CD23b isoform has
been functionally mapped to a Stat6 binding element within
the CD23b promoter termed the CD23b GAS (13, 45). We
have found that the recently cloned IRF-4 can physically
interact with Stat6 and act as a transactivator of the CD23b
GAS. Presence of BCL-6 blocks the transactivating poten-
tial of IRF-4. While BCL-6 is known to be downregulated
by CD40 (46), IRF-4 expression is markedly induced in re-
sponse to IL-4 and CD40. Since IRF-4 expression is largely
restricted to lymphoid cells, these data provide a potential
mechanism by which expression of IL-4–inducible genes can
be modulated in a cell type–specific manner. Furthermore,
the ability of CD40 and IL-4 to target the expression of mul-
tiple components of this nucleoprotein complex may under-
lie the synergistic interaction between these two pathways.
 
Materials and Methods
 
Cell Lines and Cultures.
 
The human B cell lines Ramos (ob-
tained from Dr. Seth Lederman, Columbia University) and BL-41
(obtained from Dr. Riccardo Dalla-Favera, Columbia University)
are EBV-negative Burkitt’s lymphomas. JY (obtained from Dr.
Riccardo Dalla-Favera) is an EBV-transformed lymphoblastoid B
cell line. U937 (obtained from Dr. Kathryne Calame, Columbia
University) is a monocytic cell line. All cells were grown in
IMDM supplemented with 10% fetal calf serum (Atlanta Biologi-
cals, Inc.).
Ramos B cells (10–20 
 
3
 
 10
 
6
 
) were stimulated with 0.1 
 
m
 
g/ml
of either anti-CD40 or an isotype-matched control Ab in a final
volume of 10 ml at 37
 
8
 
C for 24 h. IL-4 treatment (100 U/ml;
PeproTech) was carried out simultaneously in separate plates in a
final volume of 10 ml. Tonsillar mononuclear cells were obtained
from surgical specimens after routine tonsillectomies and were
isolated as described previously (47).
 
Abs.
 
The rabbit polyclonal antiserum against IRF-4 used in
 
electrophoretic mobility shift assay (EMSA) experiments was a gift
of Dr. Hirai, Tokoyo Universty, Tokyo, Japan (32). We subse-
quently generated our own rabbit polyclonal anti–IRF-4 antiserum
using a similar glutathione 
 
S
 
-transferase (GST)–IRF-4 (nucleotides
441–924) fusion protein as the immunogen (Babco). As previ-
ously indicated, this GST fusion protein contains a portion of the
IRF-4 protein that is specific to IRF-4 and thus avoids cross-reac-
tivity with other IRFs (32). This antiserum was used for immuno-
precipitations and immunoblot analyses. Blots were also reprobed
with a commercially available anti–IRF-4 antiserum (Santa Cruz
Biotechnology), which gave identical results. Rabbit polyclonal
antisera against human Stat6, Stat3, p65, IRF-2, IFN consensus se-
quence binding protein (ICSBP), or BCL-6, were purchased from
Santa Cruz Biotechnology, Inc. The hybridomas secreting the
anti-CD40 mAb G28-5 (IgG1) or an isotype-matched control
mAb were obtained from American Type Culture Collection.
 
DNA Constructs.
 
Full-length human IRF-4 cDNA cloned into
pBluescript vector (pBSKS-myc-IRF-4) was a gift of Dr. Riccardo
Dalla-Favera (30). The IRF-4 expression plasmid (pCEP4-IRF-4)
was constructed by cloning the entire coding region of the IRF-4
cDNA into the NotI and XhoI sites of the mammalian expression
vector pCEP4 (Invitrogen). For construction of the GST–IRF-4
expression plasmid, the entire coding region of the IRF-4 cDNA
was cloned, in frame, into the filled EcoRI site of pGEX-3X
vector (Amersham Pharmacia Biotech). The in frame junctions in
the GST–IRF-4 fusion construct were confirmed by DNA sequenc-
ing in an automated cycle sequencer (Perkin Elmer). The full-
length human BCL-6 cDNA cloned into pMT2T mammalian ex-
pression vector was a gift of Dr. Riccardo Dalla-Favera (19).
The CD23a cDNA was a gift of Dr. Kikutani, Osaka University,
Osaka, Japan (44) and Dr. Wang, Harvard University, Boston, MA
(48). To generate an antisense riboprobe of CD23a/b, a 600-bp
5
 
9
 
-EcoRI-HindIII-3
 
9
 
 fragment from the 5
 
9
 
 end of CD23a cDNA
was cloned in opposite orientation, into the HindIII and EcoRI sites
of pGEM1 in vitro transcription vector (Promega). Transcription of
the antisense RNA was driven by SP6 RNA polymerase promoter.
To prepare the CD23b GAS firefly luciferase reporter con-
struct, a trimer of the CD23b GAS element was synthesized with
flanking BamHI sites (GIBCO BRL) and then cloned into the
BamHI site (immediately upstream of minimal TK promoter) of
the TK200 luciferase reporter vector (a gift of Dr. Kathryne Ca-
lame). The CD23b promoter firefly luciferase reporter construct
in the pGL3-enhancer vector (Promega) was a gift of Dr. Seth
Lederman. The pRL-TK reporter plasmid encoding renilla lu-
ciferase to determine the transfection efficiency was purchased
from Promega.
 
DNA Binding Assays and Cell Extracts.
 
The preparation and
employment of DNA oligonucleotide probes for EMSAs have
been described previously (49) with the following modifications: 2%
glycerol was added to the polyacrylamide gel, and a reduced
poly(dI-dC) concentration (1 
 
m
 
g/reaction) was used in the bind-
ing buffer. The CD23b GAS oligonucleotides used in these studies
were as follows: CD23b GAS wild-type (wt), 5
 
9
 
-gatcGGGTGA-
ATTTCTAAGAAAGGGAC-3
 
9
 
; CD23b GAS M1, 5
 
9
 
-gatc-
GGGTGAATTTCTAAG
 
GTC
 
GGGAC-3
 
9
 
; CD23b GAS M2,
5
 
9
 
-gatcGGGTG
 
GTC
 
TTCTAAGAAAGGGAC-3
 
9
 
; and CD23b
GAS M3, 5
 
9
 
-gatcGGGTGAAT
 
GCTG
 
AAGAAAGGGAC-3
 
9
 
. Oli-
gonucleotide competition and Ab interference assays were performed
as described previously (49). Nuclear and whole cell extracts
(WCEs) were prepared as described previously (49, 50).
 
Immunoprecipitations, Western Blot Analysis, and UV Cross-linking
Assays.
 
Cell extracts were immunoprecipitated with an anti–
IRF-4, anti–BCL-6, or anti-Stat6 antiserum as described previ- 
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ously (49). The immunoprecipitates were resolved by 7% SDS-
PAGE. The gel was transferred to a nitrocellulose membrane, and
then immunoblotted with a Stat6, BCL-6, or IRF-4 Ab. The
bands were visualized by ECL (Amersham Pharmacia Biotech).
UV cross-linking was performed as described previously (49).
 
GST Pull-down Assays.
 
GST fusion proteins were expressed
in 
 
Escherichia coli
 
 DH5
 
a
 
 and affinity-purified on glutathione
(GSH)-agarose beads (Sigma Chemical Co.), as described previ-
ously (51). The concentration of each fusion protein was deter-
mined by SDS-PAGE/Coomassie staining. For pull-down assays,
lysates (
 
z
 
2 mg of total cell proteins) from control or stimulated
Ramos or JY cells were incubated with 
 
z
 
100 
 
m
 
g of GST alone
or GST–IRF-4 fusion protein immobilized onto GSH-agarose
beads in 400 
 
m
 
l of 1
 
3
 
 lysis buffer (50 mM Tris-HCl, pH 8.0, 150
mM NaCl, 0.1 mM EDTA, 0.05% NP-40, 10% glycerol, 1 mM
dithiothreitol, 1 mM Na
 
3
 
VO
 
4
 
, 1 mM PMSF, 1 
 
m
 
g/ml leupeptin, 3
 
m
 
g/ml aprotinin) for 4 h at 4
 
8
 
C with constant agitation. The
complexes were extensively washed with 1
 
3
 
 lysis buffer (contain-
ing 0.5% NP-40). The bound proteins were eluted from the
beads by boiling them in SDS-PAGE sample buffer, fractionated
on a 7% SDS-polyacrylamide gel, and then blotted onto a nitro-
cellulose membrane. The blot was probed with either a Stat6,
Stat3, or BCL-6 Ab.
 
Northern Analysis and RNase Protection Assays.
 
Total RNA was
extracted by using the RNA-STAT60 kit (TelTest, Inc.). Northern
blot analysis was performed with 10 
 
m
 
g of total RNA according to
standard protocols. The blot was probed with either a human
IRF-4 cDNA, a BCL-6 cDNA, or a glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cDNA radiolabeled by the DNA Label-
ing beads (
 
2
 
dCTP) kit (Amersham Pharmacia Biotech). RNase
protection analysis was performed as described previously (52). 10
 
m
 
g of total RNA was hybridized simultaneously to an antisense
riboprobe of CD23a/b as well as of 
 
b
 
-actin (Ambion) transcribed
by SP6 RNA Polymerase in vitro Transcription System (Promega)
using [
 
a
 
-
 
32
 
P]UTP. The annealed products were digested with ri-
bonuclease T2 (GIBCO BRL), and then analyzed on a 6% poly-
acrylamide-urea denaturing gel.
 
Transient Transfections.
 
For the transient transfection assays, 6 
 
3
 
10
 
6
 
 U937 cells were cotransfected with 25 
 
m
 
g of a CD23b GAS
wt or a CD23b GAS M2 firefly luciferase reporter plasmid and 25
 
m
 
g of various expression plasmids (as indicated in the figure leg-
end) by electroporation at 300 V and 960 
 
m
 
F with a BTX elec-
troporator as described previously (53). 5 
 
m
 
g of the pRL-TK re-
porter plasmid expressing renilla luciferase under the control of
the thymidine kinase promoter was added to each transfection as
a transfection efficiency control. JY cells (10 
 
3
 
 10
 
6
 
) were cotrans-
fected by the DEAE-dextran method (54) with 10 
 
m
 
g of the
CD23b promoter firefly luciferase reporter vector and 5 
 
m
 
g of
pRL-TK plasmid in the presence of 15 
 
m
 
g of a BCL-6 expression
plasmid (pMT2T-BCL6) or the equivalent amount of empty
pMT2T vector. After transfection, the cells were equally split
into two 2-ml cultures and then incubated for 16–24 h in the
presence or absence of IL-4 (10 ng/ml). The transfected cells
were then harvested, lysed, and assayed for luciferase activities
with the Dual Luciferase Assay System (Promega) according to
the manufacturer’s instructions. The firefly luciferase activity was
normalized on the basis of renilla luciferase activity.
 
Results
 
CD40 and IL-4 Synergistically Upregulate both CD23a and
CD23b.
 
To identify and characterize the downstream ef-
fectors of the IL-4 signaling cascade, we focused our atten-
tion on CD23, a B cell activation molecule whose regula-
tion displays lineage- and stage-specific features (41, 55).
Although IL-4 and CD40 can individually induce modest
levels of CD23, costimulation of human tonsillar B cells or
purified centroblasts with both CD40 and IL-4 leads to a
synergistic induction of surface CD23 expression (42, 43).
We found that Ramos, an EBV-negative Burkitt’s lymphoma
cell line extensively used to study the CD40 and/or IL-4
signaling pathways (56–59), mimics the physiological regu-
lation of CD23 in normal B cells (data not shown). Since
no study had previously explored the CD23 isoform(s) in-
duced in response to CD40 or the CD40 and IL-4 combina-
tion, we performed RNase protection assays. As shown in
Fig. 1, exposure of Ramos cells to either anti-CD40 Ab or
IL-4 alone preferentially upregulated the CD23a isoform.
A slight effect of IL-4 on the expression of CD23b could
also be detected. Coculturing Ramos cells with both stim-
uli led to a strong induction of both CD23a and CD23b
transcripts. Consistent with previous reports, constitutively
high levels of both CD23a and CD23b were detected in an
EBV-transformed B cell line (JY), whereas IL-4 stimulation
of a monocytic cell line, U937, only upregulated the CD23b
isoform (44, 48). 
 
b
 
-actin levels were equivalent in all lanes
(data not shown). Thus, costimulation with CD40 and IL-4
leads to a synergistic induction of both CD23 isoforms.
Figure 1. The synergistic upregulation of CD23 in response to CD40
and IL-4 reflects an induction of both CD23a and CD23b isoforms. Ra-
mos cells were cultured for 24 h either in the absence of any stimulus or
in the presence of an anti-CD40 Ab (0.1 mg/ml), an isotype-matched
control Ab (0.1 mg/ml), human IL-4 (100 U/ml), a combination of anti-
CD40 Ab plus IL-4, or a control Ab plus IL-4. U937 cells were either
unstimulated or stimulated with IL-4. JY cells were left unstimulated. Af-
ter harvesting the cells, total RNA was extracted and subjected to RNase
protection analysis. The antisense riboprobe corresponds to a 600-bp 59
EcoRI-HindIII fragment of the CD23a cDNA. The protected fragments
of 588 and 488 nucleotides correspond to two isoforms of CD23a tran-
script which differ by one base change at position 96 in the 59 untrans-
lated region, while the 381-nucleotide protected fragment corresponds to
the CD23b transcript (reference 44). 
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IRF-4 Binds to the CD23b GAS.
 
IL-4 stimulation has
been shown to lead to the rapid binding of Stat6 to a func-
tional element within the CD23b promoter termed the
CD23b GAS (13, 45). However, our RNase protection as-
say studies had revealed only a minimal induction of CD23b
in response to IL-4 alone. To determine whether addi-
tional factors could target the CD23b GAS and modulate
Stat6 activity, we first performed EMSA experiments on
Ramos cells stimulated with either IL-4, anti-CD40, or a
control Ab. As shown in Fig. 2 A, Ramos cells contain
multiple CD23b GAS binding complexes, most noticeably
a broad constitutive (C1) and a slower mobility constitutive
complex (C2). CD40 stimulation of Ramos cells led to a
decrease in the intensity of the C1 complex (Fig. 2 A).
Stimulation of Ramos cells with IL-4 activates an additional
superimposed complex that contains Stat6 (Fig. 2 C). In
contrast to Ramos cells, the appearance of the CD23b GAS
binding complexes in JY, an EBV-transformed B cell line
expressing constitutively high levels of CD23b, was strik-
ingly different. The C1 complex was absent, while the C2
complex became clearly visible (Fig. 2 A).
To dissect the CD23b GAS binding complexes, we then
carried out EMSA experiments using a panel of mutated
CD23b GAS elements as cold competitors of the radiola-
beled CD23b GAS wt probe. Interestingly, a survey of the
CD23b GAS had revealed that it contains two potential
core sequences for IRF binding (GAAT and GAAA; Table
I) (60). We thus mutated each of these two sites (M2 and
Figure 2. The CD23b GAS is
targeted by Stat6, BCL-6, and
IRF-4. (A) Ramos cells were ei-
ther unstimulated or stimulated
with anti-CD40 Ab (0.1 mg/ml),
an isotype-matched control Ab
(0.1  mg/ml), or human IL-4
(100 U/ml) for 24 h. JY cells
were left unstimulated. Nuclear extracts were then prepared and analyzed by EMSA
using a 32P-labeled CD23b GAS wt probe. (B) Ramos cells were cultured and as-
sayed as described in A. Oligonucleotide competition assays were performed either in
the absence or presence of a 100-fold molar excess of cold GAS oligonucleotides (see
Table I) added to the shift reaction as indicated. (C) Ramos and JY cells were cul-
tured as described in A. Nuclear extracts were then prepared and analyzed by EMSA
using either a 32P-labeled CD23b GAS wt probe or a 32P-labeled CD23b GAS M1
probe (Table I) as indicated. Ab interference mobility shift assays were carried out by
addition of antisera against Stat6, BCL-6, IRF-4, or control. All antisera were added
at a final dilution of 1:20 for 30 min at 48C before incubation with the probe for 20
min at 258C. (D) JY cells were unstimulated. Nuclear extracts were then prepared
and analyzed by EMSA using a 32P-labeled CD23b GAS wt probe (left). Ab inter-
ference mobility shift assays were carried out by addition of antisera against IRF-2,
IRF-4, ICSBP, or control as indicated. All antisera were added as outlined above. As a
control for the IRF-2 and ICSBP antisera, Ab interference analysis using a 32P-labeled
GBP-ISRE probe (reference 32) was simultaneously performed on Ramos extracts
(right). 
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M1, respectively) as well as a region between them (M3).
These oligonucleotide competition experiments revealed that
the C1 and C2 complexes displayed a differential pattern of
competition (Fig. 2 B). In particular, the CD23b GAS M2
mutant failed to compete the C2 complex, suggesting that this
complex targets the potential 5
 
9
 
 IRF recognition sequence.
Previous studies have shown that purified BCL-6 can bind
the CD23b GAS (22). Furthermore, expression of BCL-6 is
downregulated by CD40 stimulation of B cells, and unde-
tectable in EBV-transformed B cell lines (46, 61). These
observations suggested that the C1 complex, which we had
detected in Ramos but not in JY cells, might contain BCL-6.
Indeed, incubation of nuclear extracts from Ramos cells
with a BCL-6 antiserum, but not with a control antiserum,
led to the disappearance of the C1 complex (Fig. 2 C). These
experiments also clearly revealed the presence of the C2
complex in both untreated and IL-4–treated cells. In IL-4–
stimulated cells, an additional Stat6 complex could also be
observed.
Our cold competition experiments suggested that bind-
ing of the C2 complex to the CD23b GAS requires the
presence of a potential IRF binding site. To directly assess
whether the lymphoid-specific IRF-4 participated in the
CD23b GAS binding complexes, we then performed Ab
interference EMSA assays with an anti–IRF-4 antiserum
(32). Incubation of extracts from untreated Ramos cells
with anti–IRF-4 antiserum, but not with a control antise-
rum, supershifted the C2 complex (Fig. 2 C). Addition of
the IRF-4 antiserum completely blocked the appearance of
the C2 complex in JY extracts. Since detection of the C2
complex in Ramos cells is hindered by the presence of the
BCL-6 complex, we also performed Ab interference assays
using as a probe the CD23b GAS M1 mutant, which has
lost the ability to bind BCL-6. As shown in Fig. 2 C, this
probe clearly detected the C2 complex in Ramos cells, and
addition of the anti–IRF-4, but not a control, antiserum
led to its disappearance. Additional Ab interference assays
demonstrated that antisera against another IRF family
member, IRF-2 or ICSBP, failed to affect the appearance
of the CD23b GAS binding complexes in either JY or Ra-
mos despite appropriately supershifting complexes binding
to the guanylate binding protein (GBP)–IFN-stimulated
regulatory element (ISRE) (Fig. 2 D, and data not shown).
Furthermore, no effect of the anti–IRF-4 antiserum on the
IL-4–inducible Stat6 complex or on the IFN-
 
g
 
–inducible
Stat1 complex binding to the IRF-1 GAS was noted, indi-
cating that this effect was specific for the complex binding
to the CD23b GAS (data not shown). We have also de-
tected IRF-4 binding to a cis-element adjacent to the Stat6
binding site in the CD23a promoter (data not shown).
Thus, these data indicate that IRF-4, BCL-6, and Stat6
can all target the CD23b GAS element. Interestingly, these
experiments also suggest that binding of IRF-4 and Stat6 to
the CD23b GAS is not cooperative and can occur indepen-
dently of each other.
 
IRF-4 Physically Interacts with Stat6.
 
Interactions between
an IRF and STATs are critical for the formation of the
IFN-
 
a
 
–inducible complex, IFN-stimulated gene factor 3
(ISGF3), which contains Stat1 and Stat2 as well as p48, a
member of the IRF family (62). Since Stat6 and IRF-4 can
bind to adjacent DNA elements, we then proceeded to test
whether IRF-4 can physically interact with Stat6 by per-
forming GST fusion protein binding assays (Fig. 3 A, top).
An association of Stat6 with IRF-4 could indeed be de-
tected by incubating a GST–IRF-4 fusion protein with ex-
tracts from Ramos cells stimulated with anti-CD40, a con-
trol Ab, or human IL-4. No interaction of Stat6 with the
GST moiety alone was observed. Furthermore, reprobing
with anti-Stat3, anti-Stat1, anti-Stat2, and anti-Stat5 anti-
sera revealed that none of these STATs were able to com-
plex with IRF-4 (Fig. 3 A, bottom, and data not shown).
To confirm that the IRF-4–Stat6 interaction could occur
in vivo, we used an anti–IRF-4 antiserum to immunopre-
cipitate extracts from Ramos cells stimulated with either
anti-CD40 Ab, a control Ab, or IL-4. Consistent with our
previous observations, presence of the Stat6 protein could
be detected in the IRF-4 immunoprecipitates from both
stimulated and unstimulated Ramos lysates (Fig. 3 B, top).
Similar results were also observed in JY cells. Stripping and
reprobing of the filter with an anti–IRF-4 Ab ensured for
equal loading of the immunoprecipitates (Fig. 3 B, bot-
tom). Consistent with recent studies, which have detected
IRF-4 in both the nuclear and cytoplasmic compartments
(Riccardo Dalla-Favera, personal communication), the
IRF-4–Stat6 association can occur in the absence of IL-4
stimulation. Interestingly, in both GST and coimmunopre-
cipitation experiments the IRF-4–Stat6 interaction appears to
decrease upon stimulation of Ramos cells with the CD40 Ab.
Thus, our data indicate that IRF-4 is capable of specifi-
cally interacting with Stat6 both in vitro and in vivo.
 
Expression of IRF-4 Is Stimulated by CD40 and IL-4.
 
The
preceding experiments suggested that IRF-4 could bind a
functional element of the CD23b promoter. Since CD40
and IL-4 synergistically induce CD23b, we proceeded to
determine whether CD23b upregulation by these stimuli
was accompanied by changes in IRF-4 expression. There-
fore, we cultured Ramos cells with an anti-CD40 Ab, IL-4,
or a combination of anti-CD40 Ab and IL-4. Simultaneous
cultures with a control Ab were also included. Northern
analysis of total RNA derived from this experiment re-
 
Table I.
 
Sequence Comparison between the Wt and Mutant 
CD23b GAS Oligonucleotides
 
CD23b GAS wt 5
 
9
 
-
 
GGGTGAATTTCTAAGAAAGGGAC
 
-3
 
9
 
CD23b GAS M1 5
 
9
 
-
 
GGGTGAATTTCTAAGGTCGGGAC
 
-3
 
9
 
CD23b GAS M2 5
 
9
 
-
 
GGGTGGTCTTCTAAGAAAGGGAC
 
-3
 
9
 
CD23b GAS M3 5
 
9
 
-
 
GGGTGAATGCTGAAGAAAGGGAC
 
-3
 
9
 
Stat6 consensus
 
TTNNNNNNAA
 
IRF response element
core sequence
 
GAAA
 
BCL-6 binding site
 
GAAAATTCCTAGAAAGCATA 
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vealed that IRF-4 expression was upregulated in response
to either CD40 or IL-4 stimulation (Fig. 4 A, top). A much
stronger induction was noted when the anti-CD40 Ab was
used in conjunction with IL-4. Consistent with previous
reports (46, 61), CD40 stimulation of Ramos cells also led
to the downregulation of BCL-6 (Fig. 4 A, middle). The
same pattern of IRF-4 upregulation in response to CD40
and/or IL-4 was also detected in another EBV-negative
Burkitt’s lymphoma cell line, BL-41 (data not shown), and
by Western analysis, in human tonsillar cells (Fig. 4 B).
Strong induction of IRF-4 was also observed in response to
transfectants expressing CD40 ligand (CD40L) but not to
control transfectants, indicating that IRF-4 expression is a
physiological target of the CD40–CD40L interaction (59;
data not shown). Kinetic studies showed that induction of
IRF-4 is first noted at 2 h and can still be detected at 24 h
(data not shown). No effect on IRF-4 expression was noted
by culturing Ramos cells with either IFN-
 
g
 
 or IFN-
 
a
 
 (data
not shown). Reprobing of this Northern blot with a probe
for ICSBP, an IRF family member closely related to IRF-4
(63), revealed that the CD40 and IL-4 signaling cascades do
not upregulate ICSBP expression (data not shown). Con-
sistent with previous reports (34), we also found that IRF-4
levels are highly increased in EBV-transformed B cell lines
(data not shown). Thus, expression of IRF-4 in B cells is
specifically targeted by the CD40 and IL-4 signaling cas-
cades as well as by EBV transformation.
IRF-4 Interacts with the Krüppel Zinc Finger Transcriptional
Repressor, BCL-6. The induction of IRF-4 expression by
CD40 and IL-4 as well as by EBV suggested that IRF-4
might function as a transactivator of CD23 gene expression.
However, we had detected constitutive binding of IRF-4 to
the CD23b GAS in unstimulated Ramos cells, which only
express low levels of CD23b. We then reasoned that, in this
setting, IRF-4 function might be modulated by interaction
with a repressor. Consistent with this hypothesis, our
EMSA experiments had revealed binding of BCL-6 to the
CD23b GAS in Ramos, but not in JY cells, which express
high constitutive levels of CD23b. To assess whether IRF-4
could interact with BCL-6, we then performed UV cross-
linking experiments with a bromodeoxyuridine-substituted
CD23b GAS probe. This was followed by immunoprecipi-
Figure 3. IRF-4 interacts with Stat6. (A)
Ramos cells were stimulated as described in
the legend to Fig. 2. WCEs were then pre-
pared and incubated with immobilized
GST–IRF-4 fusion protein. Bound proteins
were eluted, resolved by 7% SDS-PAGE,
blotted onto a nitrocellulose membrane, and
then probed with a Stat6 (top) or Stat3 Ab
(bottom). Binding to immobilized GST
alone is shown as a control. (B) Ramos cells
were stimulated as described in the legend
to Fig. 2. JY cells were either unstimulated
or stimulated with IL-4 (100 U/ml). WCEs
were then prepared and immunoprecipi-
tated with an IRF-4 antiserum. The immu-
noprecipitated proteins were resolved by 7%
SDS-PAGE and then analyzed by Western blotting using a Stat6 Ab (top). The blot was later stripped and reprobed with an anti–IRF-4 antiserum (bot-
tom) using protein A–horseradish peroxidase conjugate as a secondary detection reagent to probe the primary Ab binding.
Figure 4. IRF-4 expression is upregulated in re-
sponse to CD40 and/or IL-4. (A) Ramos cells were
stimulated as described in the legend to Fig. 1. Total
RNA was then extracted, and 10 mg of the RNA was
assayed by Northern blotting as per standard protocols.
The blot was then probed with either an IRF-4 cDNA
(top), a BCL-6 cDNA (middle), or a GAPDH cDNA
(bottom) radiolabeled by random hexamer priming.
(B) Tonsillar mononuclear cells were stimulated as de-
scribed in the legend to Fig. 1. WCEs were prepared,
electrophoresed on a 7% SDS-polyacrylamide gel, and
then analyzed by Western blotting using an anti–IRF-4
Ab (top). The blot was later stripped and reprobed
with a b-actin Ab to ensure for equal loading.1843 Gupta et al.
tations with an IRF-4 antiserum, a BCL-6 antiserum, or a
Stat6 antiserum as control (Fig. 5 A). The immunoprecipi-
tates were then resolved by SDS-PAGE and Western blot-
ted. Consistent with our EMSA results (Fig. 2), an z62-kD
protein was recognized by the IRF-4 antiserum. This cor-
responds to the molecular mass of IRF-4 plus the DNA
probe. An additional cross-linked protein was also immu-
noprecipitated by the IRF-4 antiserum in Ramos, but not
in JY cells. The size of this additional protein, after correc-
tion for the probe contribution, was z90 kD, and was iden-
tical to that of the BCL-6 protein cross-linked to the CD23b
GAS as determined by simultaneous immunoprecipitation
with an anti–BCL-6 antiserum. Indeed, reprobing of the
Western blot with an anti–BCL-6 antiserum confirmed
that the p90 protein could be recognized by this antiserum
(data not shown). Thus, the anti–IRF-4 antiserum can co-
precipitate IRF-4 and BCL-6 bound to the CD23b GAS.
To determine whether interaction of IRF-4 and BCL-6
could occur independently of the presence of the CD23b
GAS, we performed pull-down assays with a GST–IRF-4
fusion protein. As shown in Fig. 5 B, incubation of a GST–
IRF-4 fusion protein with extracts from Ramos cells re-
vealed a very strong association of IRF-4 with BCL-6. No
interaction was observed with the GST moiety alone or
upon incubation of the GST–IRF-4 with JY extracts, con-
sistent with the lack of BCL-6 expression in EBV-trans-
formed B cells. We also subjected extracts from Ramos cells
cultured with or without IL-4 to immunoprecipitation as-
says with either an anti–IRF-4 or anti–BCL-6 antiserum (Fig.
5 C). This experiment demonstrated that IRF-4 and BCL-6
coimmunoprecipitated. Association of BCL-6 and IRF-4
was not affected by IL-4 treatment. Surprisingly, we did not
detect increased levels of IRF-4 in our immunoprecipita-
tions of IL-4– or CD40-treated extracts (Fig. 3 B and Fig.
5 C), despite an induction of IRF-4 levels by these stimula-
tions (Fig. 4). We suspect that this may be due either to a
limited ability of this antiserum to immunoprecipitate in-
creasing amounts of IRF-4 or to the ability of IRF-4 upon
IL-4–CD40 treatment to form alternative complexes that
cannot be recognized by this antiserum.
To further corroborate the specificity of the association
of IRF-4 with BCL-6 and Stat6, we also performed coim-
munoprecipitation experiments with either an anti–IRF-4
or an antiserum against a nuclear factor kB (NF-kB) family
member, p65. These assays were conducted on extracts from
JY cells, which constitutively express p65 in the nucleus
(49; Fig. 5 D). These experiments failed to detect an associa-
tion of IRF-4 with p65.
Figure 5. IRF-4 interacts with BCL-6. (A) Ra-
mos cells were either unstimulated or stimulated
with IL-4 (100 U/ml). JY cells were unstimulated.
Nuclear extracts were then prepared as described in
the legend to Fig. 2, and incubated with a radiola-
beled 5-bromodeoxyuridine–substituted CD23b
GAS wt probe (BUdR-CD23b GAS wt) in a stan-
dard shift reaction. DNA–protein complexes were
irradiated twice with 1,000 mJ of UV, and then
immunoprecipitated (IP) with either an IRF-4, a
BCL-6, or a Stat6 antiserum. The immunoprecipi-
tates were resolved by 7% SDS-PAGE, transferred
to a nitrocellulose membrane, and then exposed to
an x-ray film. No cross-linking was detected in the
absence of UV irradiation. (B) Ramos and JY cells
were cultured as described in A. Nuclear extracts
were then prepared and incubated with immobi-
lized GST–IRF-4 fusion protein. Bound proteins
were eluted, fractionated by 7% SDS-PAGE, trans-
ferred to a nitrocellulose membrane, and then
probed with a BCL-6 antiserum. Binding to im-
mobilized GST alone is shown as a control. (C)
Ramos cells were either unstimulated or stimulated
with IL-4 (100 U/ml). Nuclear extracts were pre-
pared and immunoprecipitated with either an anti–
IRF-4 or an anti–BCL-6 antiserum. The immune
complexes were resolved by 7% SDS-PAGE, and
then analyzed by Western blotting using an anti–
BCL-6 antiserum (top). The blot was later stripped
and reprobed with an anti–IRF-4 antiserum (bot-
tom), as described in the legend to Fig. 3. (D) JY
cells were unstimulated. Nuclear extracts were pre-
pared and immunoprecipitated with either an anti–
IRF-4 or an anti-p65 antiserum. The immune
complexes were resolved by 7% SDS-PAGE, and
then analyzed by Western blotting using an anti-
p65 antiserum (top). The blot was later stripped and
reprobed with an anti–IRF-4 antiserum (bottom),
as described above.1844 Modulation of IL-4 Signaling by IRF-4
These studies thus indicate that IRF-4 can interact with
the Krüppel zinc finger transcriptional repressor, BCL-6,
both in vitro and in vivo. Furthermore, no such interaction
is detected in cells (JY) that express high levels of CD23b,
suggesting that the presence of BCL-6 affects the functional
ability of IRF-4 to modulate CD23b transcription.
The Ability of IRF-4 to Transactivate CD23b Can Be Blocked
by BCL-6. To directly assess whether IRF-4, in the ab-
sence of BCL-6, could function as a transactivator of CD23b,
we performed transient transfection assays in U937 cells, a
monocytic cell line that is capable of activating Stat6 in re-
sponse to IL-4, but lacks both IRF-4 and BCL-6. Cotrans-
fection of an IRF-4 expression vector with a luciferase re-
porter construct driven by an oligomerized CD23b GAS
wt element resulted in a threefold induction in the luciferase
activity, suggesting that IRF-4 can act as a transactivator of
CD23b in the absence of Stat6 activation (Fig. 6 A). This
level of induction was similar to that observed upon stimu-
lation of U937 with IL-4. Interestingly, cotransfection of
IRF-4 augmented, albeit not in a synergistic manner, the in-
duction of the CD23b GAS wt reporter construct in response
to IL-4. Consistent with the results of our EMSA experi-
ments, a reporter construct driven by a mutant CD23b GAS
element, which binds Stat6 but not IRF-4 (CD23b GAS M2,
Fig. 2 B), displayed a normal IL-4 inducibility but could not
be activated by IRF-4 cotransfection (Fig. 6 A). Furthermore,
overexpression of IRF-4 was unable to enhance the IL-4–
mediated activation of this CD23b GAS M2 reporter con-
struct. Thus, these data suggest that optimal transactivation of
CD23b requires the presence of both Stat6 and IRF-4.
Since BCL-6 is known to repress Stat6 function, we then
proceeded to determine whether BCL-6 could block IRF-4
function. Indeed, cotransfection of BCL-6, but not of an
empty vector, with IRF-4 was able to repress the ability of
IRF-4 to induce the activity of the CD23b GAS reporter
construct (Fig. 6 B). A similar inhibitory effect was also de-
tected when BCL-6 was cotransfected with a reporter con-
struct driven by the CD23b promoter in JY, an EBV-trans-
formed B cell line, which constitutively expresses high levels
of IRF-4 but no activated Stat6 (Fig. 6 C). These studies
thus indicate that IRF-4 can transactivate the CD23b GAS
and that BCL-6 can block IRF-4 function independently
of its inhibitory effects on Stat6.
Discussion
IRF-4, a Lineage-specific Effector of the IL-4 and CD40 Sig-
naling Pathways. Biochemical and genetic studies have dem-
onstrated that Stat6 plays a key role in IL-4 signaling (10).
However, the rapid activation of Stat6 cannot solely account
for the complex biological activities of IL-4 (1, 3). The IL-4
signaling pathway must thus use additional effector mole-
cules. Our studies demonstrate that IRF-4 is both a target
and a modulator of the IL-4 signaling pathway. This dual role
of IRF-4 is thus reminiscent of that of IRF-1 in the IFN sig-
naling cascade (26). In contrast to the IL-4 induction of Stat6,
which has been detected in a wide variety of cells (13–17),
IRF-4 expression is largely restricted to the lymphoid com-
partment (31, 32, 34). Thus, the recruitment of IRF-4 by
the IL-4 signaling pathway provides a potential mechanism
Figure 6. Effects of IRF-4 on the transactivation of CD23b. (A) U937 cells were cotransfected with a luciferase reporter construct driven by either an
oligomerized CD23b GAS wt or an oligomerized CD23b GAS M2 element, and either an IRF-4 expression plasmid (pCEP4-IRF4) or equivalent
amounts of empty vector. The transfected cells were equally split into two 2-ml aliquots and then incubated for 24 h in the presence or absence of IL-4
(10 ng/ml). The data are presented relative to the activity of the reporter construct in control U937 cells, which was set to 1.0, as indicated, in each ex-
periment. Results show the mean 6 SE of four independent experiments. (B) U937 cells were cotransfected with a luciferase reporter construct driven
by an oligomerized CD23b GAS wt element, and an IRF-4 expression plasmid (pCEP4-IRF4) in the presence of either an BCL-6 expression vector
(pMT2T-BCL6) or equivalent amounts of empty pMT2T vector, as indicated. The transfected cells were left unstimulated for 16 h. The data are pre-
sented relative to the activity of the reporter construct in control U937 cells, which was set to 1.0, as indicated, in each experiment. Results show the
mean 6 SE of three independent experiments. (C) JY cells were cotransfected with a CD23b promoter luciferase reporter construct in the presence of an
expression plasmid for BCL-6 (pMT2T-BCL6) or of equivalent amounts of empty pMT2T vector. The transfected cells were left unstimulated for 16 h.
The data are presented relative to the activity of the reporter construct in control JY cells, which was set to 1.0, as indicated, in each experiment. Results
show the mean 6 SE of three independent experiments.1845 Gupta et al.
by which this cytokine can regulate the expression of target
genes in a lineage-specific manner.
Similarly to IRF-1, whose induction is not restricted to
the IFN pathway (64, 65), we found that the expression of
IRF-4 in B cells can be independently upregulated by stim-
ulation via the CD40 receptor. CD40 engagement is also
known to lead to the rapid activation of the NF-kB/rel fam-
ily of transcription factors (4). Although other IRFs have been
shown to interact with NF-kB/rel proteins (66–68), we
did not detect a physical interaction of IRF-4 with p65
(Fig. 5 D). However, this finding does not exclude that IRF-4
may be able to associate with other NF-kB family members
and/or functionally modulate the activity of CD40-induc-
ible NF-kB complexes. Such an interaction may allow
IRF-4 to participate in the regulation of genes that are acti-
vated in response to CD40 alone.
Our studies indicate that costimulation of B cells with
CD40 and IL-4 leads to maximal IRF-4 induction. This is
accompanied by the simultaneous CD40-mediated down-
regulation of BCL-6 (Fig. 4 A), consistent with previous
reports (46, 61). Since germinal center T cells have been
shown to express CD40L as well as IL-4 (69), the transcrip-
tional events triggered by activation of B cells with both
stimuli are physiologically relevant. Thus, one may predict
that B cells that have been successfully selected in the ger-
minal center and have received appropriate T cell help
should express high levels of IRF-4 in addition to low or
absent BCL-6. In support of this notion, a small subpopula-
tion of centrocytes with such a phenotype has been identi-
fied in close apposition to follicular dendritic cells. These
cells have been postulated to represent “surviving centro-
cytes” (Riccardo Dalla-Favera, personal communication).
The coordinated induction of IRF-4 and downregulation
of BCL-6 may thus be an important step in the progression
of B cells toward the terminal stages of differentiation.
Interplay between IRF-4, Stat6, and BCL-6. Our studies
demonstrate that Stat6 and IRF-4 can physically interact. Pre-
liminary experiments suggest that association of IRF-4 with
Stat6 involves the COOH-terminal region of IRF-4. This
portion of IRF-4 contains a putative a-helical region, which
displays strong homology to the STAT-interacting domain of
p48, the IRF component of the ISGF3 complex (63, 70). As
in the case of the p48–Stat2 complex (71), tyrosine phosphor-
ylation of Stat6 does not appear to be needed for its associa-
tion with IRF-4. However, unlike the ISGF3 complex (70,
72), IRF-4 does not appear to be involved in recruiting Stat6
to the CD23b GAS. Our inability to detect a cooperative
complex containing both IRF-4 and Stat6 also contrasts with
the strong phosphorylation-dependent cooperative interac-
tion between IRF-4 and the Ets protein, PU.1 (29, 35, 36).
Our transient transfection experiments indicate that
IRF-4 can act as a transactivator and augment the Stat6 in-
ducibility of CD23b. Our studies have revealed an additive
rather than a synergistic interaction between IRF-4 and
Stat6, suggesting that recapitulation of the synergistic in-
duction of CD23b in vitro may require regions flanking the
CD23b GAS and/or additional components. For example,
studies of the IFN-b enhanceosome, a model system for
transcriptional synergism, have demonstrated that this regu-
latory region (2110 to 253) contains multiple IRF-1 bind-
ing sites (73). Consistent with this notion, our survey of the
CD23b promoter has revealed that the regions flanking the
CD23b GAS may contain additional IRF-4 binding sites.
Our inability to detect enhanced IRF-4 DNA binding in
EMSAs upon IL-4 treatment (Fig. 2 A) may thus be due to
the lack of these additional sites in the probes used. Al-
though, in the CD23 system, IRF-4 acts as a positive regu-
lator, IRF-4 contains multiple regions with transactivation
and/or repressing potential (74–77). Therefore, the precise
outcome of the Stat6–IRF-4 interaction is likely to be dic-
tated by the specific arrangement of their DNA binding
sites as well as by the presence of additional cofactors.
Indeed, our studies suggest that the function of IRF-4
can be profoundly affected by the presence of the Krüppel
zinc finger transcriptional repressor, BCL-6 (19–21, 78, 79).
BCL-6 is able to repress IRF-4 function in the absence of
Stat6. This may allow BCL-6 to modulate the expression
of Stat6-independent target genes. Indeed, we have found
that BCL-6 binds to the IRF-4 binding site present in the
Igk 39 enhancer (35, 36; data not shown). In contrast to the
CD23b GAS, this DNA element does not bind Stat6. Thus,
the BCL-6–IRF-4 interaction may underlie some of the
defects exhibited by the BCL-6–deficient mice that are not
corrected by the lack of Stat6 (24).
Various mechanisms may account for the repressive ef-
fects of BCL-6 on IRF-4 function. In addition to the
known ability of BCL-6 to recruit the corepressor machin-
ery (80–83), BCL-6 may prevent high-affinity DNA bind-
ing by IRF-4 as suggested by our UV cross-linking ex-
periments, which detected stronger CD23b GAS–IRF-4
complexes in the absence of BCL-6. Furthermore, previ-
ous studies have indicated that IRF-4 contains an inhibi-
tory region (amino acids 207–300) that can mask its own
transactivation domain (84). Thus, BCL-6 may maintain
IRF-4 in an autoinhibitory state. IRFs have previously been
shown to be critical components of the virally induced
IFN-b enhanceosome (73). Interestingly, another member
of the Krüppel zinc finger family of transcription factors,
PRDI-BF/Blimp1 (85–87), can bind to one of the IRF
binding sites within the IFN-b enhanceosome and act as a
repressor of IFN-b gene expression (85). Thus, interaction
between IRFs and Krüppel proteins may be a conserved fea-
ture of the transcriptional regulation of a variety of genes.
The ability of the CD23b GAS to bind an IRF family
member as well as its organizational features are indeed rem-
iniscent of regulatory DNA elements targeted by enhance-
osomes (88). This suggests that the CD23b GAS and its
flanking regions may function in the assembly of higher-
order transcriptional complexes. The synergistic induction
of CD23b by the CD40 and IL-4 signaling pathways may
thus result from their ability to simultaneously target the
expression/function of Stat6, IRF-4, and BCL-6, leading
to a profound remodeling of the architecture of this nucleo-
protein complex. Although we have been unable to clearly
demonstrate formation of a trimolecular complex consist-
ing of Stat6, BCL-6, and IRF-4, prolonged exposures of our1846 Modulation of IL-4 Signaling by IRF-4
UV cross-linking experiments (Fig. 5 A) have revealed that
the IRF-4 antiserum can immunoprecipitate, in addition to
IRF-4 and BCL-6, a faint band of mobility identical to that
of Stat6. Assembly of this complex may thus require spe-
cific three-dimensional contacts, which we are unable to
fully reproduce with the techniques available to us. Alterna-
tively, some of the interactions between Stat6, IRF-4, and
BCL-6 could be mediated by additional cofactors. These
findings thus lend support to the notion that assembly of
these enhanceosome-like complexes may represent ideal
targets for the final integration of signaling pathways (73).
Furthermore, presence of lineage-specific components like
IRF-4 and stage-specific repressors like BCL-6 within
these complexes would endow cells with the ability to reg-
ulate gene expression in response to signals such as CD40
and IL-4 in a context-appropriate manner.
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